List of Excipients in Branded Drug REYATAZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	REYATAZ	atazanavir	0003-3624	ALCOHOL
ER Squibb & Sons LLC	REYATAZ	atazanavir	0003-3624	AMMONIA
ER Squibb & Sons LLC	REYATAZ	atazanavir	0003-3624	BUTYL ALCOHOL

Reyataz Excipient Strategy and Commercial Opportunities for Atazanavir

Last updated: August 5, 2026

Reyataz is the branded formulation of atazanavir sulfate, an HIV-1 protease inhibitor developed by Bristol-Myers Squibb. Its commercial opportunity has shifted from primary branded sales to generic supply, pediatric formulations, differentiated oral delivery, global access, and reformulation strategies that address atazanavir's pH-dependent solubility and food requirements.

What is Reyataz and how is atazanavir formulated?

Reyataz contains atazanavir sulfate, a poorly water-soluble antiretroviral whose absorption depends on gastric acidity and administration with food. The product has been marketed primarily as capsules and oral powder.

Product	Strength or presentation	Route	Primary excipient strategy
Reyataz capsules	100, 150, 200, 300 mg	Oral	Lactose-based capsule fill with crospovidone and magnesium stearate
Reyataz oral powder	50 mg per packet, equivalent to 10 mL after reconstitution	Oral	Sucrose-based powder with flavoring and silica-based flow control
Atazanavir sulfate API	Dose-dependent	Oral	Salt form selected to improve pharmaceutical handling and oral exposure

The US label identifies lactose monohydrate, crospovidone and magnesium stearate in the capsule fill. Capsule shells contain gelatin, titanium dioxide and colorants. The oral powder contains sucrose and flavoring excipients, with formulation components intended to support powder flow and dispersion after reconstitution.[1]

Reyataz is administered with food. Acid-reducing agents can materially lower atazanavir exposure, creating a formulation and labeling constraint that is central to generic and reformulation strategy.[1,2]

What excipients protect the performance of Reyataz?

The excipient system is relatively conventional, but each component has a defined technical role.

Lactose monohydrate

Lactose is the principal diluent in the capsule formulation. It provides bulk, supports blend uniformity and enables a practical fill weight across multiple strengths. Its commercial advantages include low cost, broad supplier availability and established regulatory use.

The main limitation is lactose intolerance and the presence of milk-derived material in some supply chains. A lactose-free generic could target patients, markets or institutional buyers that prefer reduced excipient complexity.

Crospovidone

Crospovidone functions as a superdisintegrant. Rapid capsule-fill disintegration is important because atazanavir has limited aqueous solubility and relies on dissolution under acidic gastrointestinal conditions.

A generic manufacturer could evaluate crospovidone particle size, level and grade to improve dispersion without changing the active ingredient. Any change would require comparative dissolution and bioequivalence support.

Magnesium stearate

Magnesium stearate provides lubrication during capsule manufacture. Excessive use or prolonged blending can reduce wetting and slow dissolution, which is relevant for a poorly soluble drug. Control of lubricant concentration, blending time and specific surface area may provide a low-cost process optimization opportunity.

Sucrose and flavoring in oral powder

The powder formulation uses sucrose to improve palatability and bulk. Flavoring supports pediatric administration. The commercial tradeoff is that high sugar content is less attractive for patients requiring chronic treatment, including children with dental or metabolic concerns.

A sugar-reduced or sugar-free powder, oral granule or dispersible tablet could offer a differentiation route, provided taste, dose uniformity, dissolution and bioequivalence are demonstrated.

How does atazanavir solubility affect excipient selection?

Atazanavir is a weakly basic, pH-dependent compound. Its solubility is higher in acidic conditions and falls as gastric pH increases.[1,2] This affects both formulation development and commercial positioning.

Key formulation variables include:

1. Particle size and surface area of atazanavir sulfate.
2. Wetting and disintegration performance.
3. Microenvironmental pH inside the dosage form.
4. Compatibility with food and beverage administration.
5. Sensitivity to antacids, H2-receptor antagonists and proton-pump inhibitors.
6. Moisture control and solid-state stability.

Potential enabling technologies include amorphous solid dispersions, lipid-based systems, nanocrystals, spray-dried dispersions, pH-modifying excipient systems and immediate-release granules. These approaches may improve dissolution or reduce variability, but they also increase manufacturing complexity and regulatory burden.

A commercial reformulation should not pursue solubility enhancement in isolation. The stronger target is a product that reduces administration restrictions, improves pediatric acceptability or allows more reliable exposure when acid-reducing medicines are used.

What formulation opportunities exist for generic atazanavir?

The conventional capsule is the lowest-risk opportunity. It can compete on price, supply reliability and regional registration. Higher-value opportunities require a clear clinical or operational advantage.

Opportunity	Technical objective	Commercial value	Main barrier
Lactose-free capsule	Replace lactose with mannitol, microcrystalline cellulose or another diluent	Access to lactose-sensitive or institutional markets	Bioequivalence and blend uniformity
Sugar-free oral powder	Reduce or remove sucrose	Pediatric and chronic-use differentiation	Taste masking and dose accuracy
Ready-to-use suspension	Eliminate reconstitution steps	Improved pediatric convenience	Physical stability and microbial control
Taste-masked granules	Improve administration in children	Potential premium positioning	Palatability and manufacturing cost
Fast-disintegrating tablet	Reduce swallowing burden	Adult and adolescent convenience	Dissolution under variable gastric pH
Lipid or amorphous formulation	Improve apparent solubility	Potentially lower food dependence	New formulation development and regulatory evidence
Fixed-dose combination	Combine with other antiretrovirals	Simplify HIV treatment	Compatibility, dose flexibility and existing guideline preferences
Heat-stable global product	Improve distribution in low-resource markets	Expanded geographic access	Stability, packaging and local registration

The most practical near-term opportunity is a differentiated pediatric dosage form. The oral powder already establishes a pediatric route, but a lower-sugar, easier-to-administer product could compete on usability rather than only price.

What FDA regulatory status applies to Reyataz and atazanavir?

FDA approved Reyataz capsules in 2003 for treatment of HIV-1 infection in combination with other antiretroviral agents. The agency later approved an oral powder formulation for pediatric use. Atazanavir is also available through abbreviated new drug applications in certain markets, subject to the scope of approved strengths and dosage forms.[1,3]

Regulatory issue	Commercial implication
Original NDA approval	Establishes the reference product for US bioequivalence
Capsule dosage forms	Most accessible route for generic competition
Oral powder	Higher technical and pediatric differentiation potential
Food requirement	Must be addressed in labeling and clinical development
Acid-reducing interactions	Limits broad positioning as a simple once-daily product
Pediatric labeling	Supports investment in palatability and dose flexibility
Salt form	Atazanavir sulfate is the relevant reference-product form

A formulation that changes excipient composition but retains the same active moiety and dosage form may qualify for an ANDA if it satisfies sameness, pharmaceutical equivalence and bioequivalence requirements. A materially redesigned delivery system may require a different regulatory pathway.

When did Reyataz lose exclusivity and what is the generic entry risk?

Reyataz's original small-molecule exclusivity and principal patent protection have expired or reached the end of their commercial protection period in the United States. Generic entry risk is therefore established rather than prospective for the core capsule product.

The commercial risk differs by product:

Product segment	Generic entry risk	Remaining differentiation
Standard capsules	High	Price, supply and regional registration
Pediatric powder	Moderate to high	Palatability, sugar reduction and dose convenience
Novel suspension	Lower initially	Formulation patents and clinical utility
Fixed-dose combination	Moderate	Combination patents and guideline adoption
Global tender supply	High price pressure	Manufacturing scale and reliable quality

Paragraph IV challenges were relevant during the historical patent run-up. The current commercial focus is less likely to be an originator patent challenge and more likely to involve abbreviated applications, formulation design-arounds and regional generic registrations. An applicant must still review the current FDA Orange Book, applicable pediatric exclusivity, patent certifications and any jurisdiction-specific protections before launch.[3]

What patents protect atazanavir and its formulations?

Atazanavir protection historically covered the active compound, pharmaceutical salts, compositions and methods of treating HIV infection. The core patent family was associated with Bristol-Myers Squibb and related entities. The most important expired protection centered on the atazanavir compound and its sulfate salt.

Potentially relevant patent categories include:

• Atazanavir compound claims.
• Atazanavir sulfate salt claims.
• Pharmaceutical composition claims.
• Methods of treating HIV infection.
• Combination treatment with ritonavir.
• Specific dosing regimens.
• Pediatric administration.
• Solid-state or particle-size forms.
• Manufacturing and purification processes.

The practical freedom-to-operate question is formulation-specific. A standard atazanavir sulfate capsule may face little core composition risk after patent expiration, while a new solid form, amorphous dispersion, pH-modified system or combination product could encounter later-expiring formulation or method claims.

A new entrant should screen US, European, Japanese, Chinese, Indian and Latin American patent registers separately. Patent expiry, enforceability and regulatory linkage differ by jurisdiction. Orange Book-listed patents are relevant to US ANDA strategy, while national patent registers and data exclusivity rules control many non-US markets.[3,4]

What formulation patents could support a new atazanavir product?

The strongest patentable opportunities are likely to involve measurable performance improvements rather than routine excipient substitution.

Reduced food dependence

A formulation that produces equivalent exposure under fasting and fed conditions could have substantial clinical value. It could reduce adherence failures and simplify use with other medicines.

Reduced acid-suppression sensitivity

A dosage form that maintains exposure at moderately elevated gastric pH could target patients using proton-pump inhibitors or H2 blockers. This would require strong pharmacokinetic evidence because the interaction is a known characteristic of atazanavir.

Pediatric delivery

Claims could focus on a stable, palatable composition with defined particle size, reconstitution time, dose uniformity and storage conditions. Pediatric method-of-use claims may complement composition claims, although their value depends on enforceability and market adoption.

Manufacturing process

A process that improves impurity control, particle-size consistency, yield or solid-state stability could support licensing or supply agreements even where the finished-dose product is not strongly differentiated.

How does Reyataz compare with competing HIV protease inhibitors?

Atazanavir's commercial advantages include once-daily dosing, a relatively favorable lipid profile compared with some older protease inhibitors and established use with ritonavir or cobicistat boosting. Its disadvantages include acid-reducing-agent interactions, food requirements, hyperbilirubinemia and the decline in protease-inhibitor use relative to integrase inhibitor regimens.[2,5]

Drug	Formulation opportunity	Key commercial constraint
Atazanavir	Pediatric powder, low-acid-dependence formulation	Gastric pH and food effects
Darunavir	Tablets, oral suspension, combination products	Strong competition from integrase-based regimens
Lopinavir/ritonavir	Liquid and tablets	Tolerability and metabolic profile
Dolutegravir	Tablets and dispersible products	High generic and combination competition
Bictegravir combinations	Fixed-dose tablets	Strong originator IP and combination positioning

The main strategic question is whether a reformulated atazanavir product can solve a clinically relevant problem. A lower-cost capsule alone has limited strategic value in markets where integrase inhibitors dominate treatment guidelines.

Which companies could challenge or commercialize atazanavir?

Potential commercial participants include established generic manufacturers, HIV-focused suppliers, contract development and manufacturing organizations, and public-sector procurement specialists. The relevant capabilities are:

• High-potency API handling.
• Low-dose blend uniformity.
• Solid-state characterization.
• Pediatric taste masking.
• Bioequivalence execution.
• Global regulatory submissions.
• Stable supply for government tenders.
• Packaging suitable for hot and humid climates.

A licensing deal would be most attractive where one party owns a differentiated formulation and the other has regulatory registrations, manufacturing capacity or tender access. The value of a deal depends more on the product's route-to-market advantage than on the expired core active-ingredient patent estate.

What revenue exposure does Reyataz create?

Reyataz was a major commercial HIV product for Bristol-Myers Squibb, with historical annual sales above $1 billion before the shift toward generic competition and newer antiretroviral classes.[6] Current value is concentrated in residual branded demand, markets with limited generic penetration, pediatric supply and institutional procurement.

Revenue exposure for a new entrant should be modeled by segment:

Revenue pool	Margin profile	Strategic assessment
US standard capsules	Low to moderate	Volume opportunity, substantial price pressure
European generic markets	Low	Tender and reference-pricing pressure
Emerging markets	Low to moderate	Larger access need, payment and registration risk
Pediatric formulations	Moderate to high	Smaller volume, better differentiation
Novel delivery systems	Potentially high	Development and patent risk
API supply	Moderate	Scale and quality-system advantage required

How strong is the patent estate for a new atazanavir excipient product?

The expired core active-ingredient estate provides limited defensive value for a new commercial product. A new entrant would need to build protection around the formulation, manufacturing process, dosage form, pediatric use or a clinically meaningful pharmacokinetic benefit.

Patent strength is highest when claims are tied to:

• Defined excipient ratios.
• Particle-size or polymorph parameters.
• Demonstrated dissolution or exposure advantages.
• Reduced food or acid-suppression effects.
• Stable reconstituted suspensions.
• Pediatric dosing and administration.
• Commercially difficult manufacturing steps.

Routine replacement of lactose, magnesium stearate or a flavoring agent is unlikely to produce a durable patent position without an unexpected technical effect.

Key Takeaways

• Reyataz contains atazanavir sulfate and uses a relatively conventional capsule excipient system.
• Lactose, crospovidone and magnesium stearate support capsule bulk, disintegration and manufacturability.
• The oral powder creates the clearest existing platform for pediatric reformulation.
• The largest technical opportunity is reducing food dependence or sensitivity to elevated gastric pH.
• Standard capsule competition is primarily a cost and supply-chain business because core exclusivity has expired.
• Sugar-free, taste-masked and ready-to-use pediatric products offer stronger differentiation.
• New patents should focus on measurable formulation, process or administration benefits.
• Atazanavir competes against newer integrase inhibitor regimens, limiting the value of undifferentiated reformulation.
• Manufacturing scale, bioequivalence capability and global tender access are more important than legacy brand recognition for generic entry.

FAQs

Is Reyataz still commercially relevant?

Yes, but mainly in generic, pediatric, developing-market and institutional channels. Its strategic relevance is lower in first-line adult HIV treatment because integrase inhibitor regimens are widely preferred.

Can lactose be removed from an atazanavir capsule?

Yes, a lactose-free formulation is technically feasible. The replacement excipient must preserve blend uniformity, capsule filling, disintegration, dissolution and bioequivalence.

Does atazanavir require a pH-modifying excipient?

Not necessarily. The reference product relies on gastric acidity and administration conditions. A pH-modifying excipient could be commercially valuable, but it would require formulation and pharmacokinetic validation.

Is an atazanavir oral suspension more attractive than a capsule?

It may be more attractive for pediatric use, but it has higher development risk because of taste, sedimentation, microbial stability, reconstitution and dose-uniformity requirements.

Can a new atazanavir formulation receive patent protection?

Yes. Protection is more likely for a formulation with a defined composition and demonstrated technical effect than for a routine excipient substitution.

References

1. U.S. Food and Drug Administration. (2023). Reyataz (atazanavir sulfate) prescribing information. Bristol-Myers Squibb Company.

2. European Medicines Agency. (2021). Reyataz: EPAR product information. European Medicines Agency.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. World Intellectual Property Organization. (2024). PATENTSCOPE database. World Intellectual Property Organization.

5. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.

6. Bristol-Myers Squibb Company. (2017). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.